Psychological support program for amyloidosis patients and families
Part of Genetic & congenital, Heart & circulation clinical trials.
This study tests a structured psychological support program for people with hereditary transthyretin amyloidosis (ATTRv) with heart involvement, their caregivers, and those who carry the gene but have no symptoms yet. The goal is to see if the program is practical and well-accepted.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older
- You must be fluent in Italian
- You are a patient with hereditary ATTR amyloidosis affecting the heart, or a presymptomatic gene carrier, or a caregiver for someone with this condition
- You are being followed at the Amyloidosis Center in Pavia, Italy
- You must sign a consent form agreeing to take part
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for “biomarkers” (measurable signs in blood or other tests) to understand inherited transthyretin amyloidosis, including in people who have not yet developed symptoms. Results may help researchers track the condition earlier and better understand how it changes over time.
This study is observing people with amyloidosis or those who carry a specific gene mutation (transthyretin) to learn more about the condition. It does not test any new treatment, but may help researchers understand how the disease affects people.
This trial builds an Italian online network to learn from people who may have amyloidosis (an abnormal protein condition). It collects information from participating centers and could help doctors better understand different types of amyloidosis.
This trial is for people with a specific inherited form of amyloidosis caused by a change in the TTR gene. It offers a comprehensive care program to help manage this rare condition.
This study follows patients with ATTR amyloidosis over time to understand how the disease affects them. It does not test a new treatment—instead, it asks you to fill out questionnaires about your health and symptoms to help doctors learn more about the condition.
This is an observational study (no study drug) for people with transthyretin (TTR)–mediated amyloidosis, including people who carry certain gene changes before symptoms begin. It may help researchers better understand how the disease affects health over time and what to measure in future treatments.
Hear when a new Hereditary Transthyretin Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.